KH 001 - HysensBio
Alternative Names: KH-001 - HysensBioLatest Information Update: 04 Sep 2024
At a glance
- Originator HysensBio
- Class Anti-infectives; Antiallergics; Peptides
- Mechanism of Action Odontoblast stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Dental caries; Hypersensitivity
Most Recent Events
- 30 Aug 2024 HysensBio plans a phase II trial for Dental caries (In adults) in South Korea (Topical), in September 2024 (NCT06580678 )
- 18 Jun 2024 HysensBio plans a phase II trial for Hypersensitivity in USA (Topical) (NCT06464939)
- 28 Feb 2024 Phase-I/II clinical trials in Dental caries (unspecified route) (HysensBio Pipeline, February 2024)